I am a
Home I AM A Search Login

Papers of the Week


Papers: 4 May 2024 - 10 May 2024


2024 May 08


Headache


38717120

Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100, a dry powder formulation of dihydroergotamine versus intravenous dihydroergotamine: A Phase 1 randomized, double-blind study in healthy adults.

Authors

Bodie S, Curran AK, Gonzalez-Nelson AC, Perry JM, Manning DC, Wasilewski MM

Abstract

Intravenous dihydroergotamine (DHE) has well-established efficacy for the acute treatment of migraine, but its use is limited by the need for in-hospital administration and the nausea/vomiting associated with a high maximum plasma concentration (C). Inhalation is an alternative to intravenous dosing. The surface area of the lung allows for rapid absorption of a self-administered dose.